Association of CTLA-4 (AT)n Variants in Basal Cell Carcinoma and Squamous Cell Carcinoma Patients from Western Mexico
-
Published:2024-08-01
Issue:8
Volume:46
Page:8368-8375
-
ISSN:1467-3045
-
Container-title:Current Issues in Molecular Biology
-
language:en
-
Short-container-title:CIMB
Author:
Rojas-Diaz Jose Manuel12ORCID, Zambrano-Román Marianela1ORCID, Padilla-Gutiérrez Jorge Ramón1ORCID, Valle Yeminia1ORCID, Muñoz-Valle José Francisco1ORCID, Valdés-Alvarado Emmanuel1ORCID
Affiliation:
1. Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico 2. Instituto de Investigación en Enfermedades Crónico Degenerativas, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
Abstract
The incidence of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) is constantly increasing, becoming a significant health problem. CTLA-4 is a critical immune checkpoint, and it has been suggested that a variant of variable-number tandem repeat in the 3’-UTR of its gene, known as (AT)n, may be associated with a higher susceptibility to some cancers; however, little is known about genetic variants of the CTLA-4 gene in NMSC. To establish the association of this genetic variant in the CTLA-4 gene with the susceptibility of NMSC carcinogenesis in the Western Mexican population, samples from 150 BCC patients, 150 SCC patients, and 150 healthy individuals as the reference group (RG) were analyzed by endpoint PCR, followed by electrophoresis to genotype the samples. We found that the short-repeat 104/104 bp genotype may be a risk factor for BBC carcinogens (OR = 2.92, p = 0.03), whereas the long-repeat 106/106 bp genotype may be a protective factor for both BCC (OR = 0.13, p = 0.01) and SCC (OR = 0.32, p = 0.01) susceptibility. Our results show that in the Western Mexican population, long-repeat (AT)n variants in the CTLA-4 gene are associated with a protective factor in BCC and SCC. In contrast, short repeats are associated with a risk factor.
Funder
University of Guadalajara
Reference38 articles.
1. Hu, W., Fang, L., Ni, R., Zhang, H., and Pan, G. (2022). Changing Trends in the Disease Burden of Non-Melanoma Skin Cancer Globally from 1990 to 2019 and Its Predicted Level in 25 Years. BMC Cancer, 22. 2. Zavdy, O., Coreanu, T., Bar-On, D.Y., Ritter, A., Bachar, G., Shpitzer, T., Kurman, N., Mansour, M., Ad-El, D., and Rozovski, U. (2023). Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients—A Comparison between Different Immunomodulating Conditions. Cancers, 15. 3. Epidemiología del cáncer de piel en pacientes de la Clínica de Dermato-oncología del Centro Dermatológico Dr. Ladislao de la Pascua. Estudio retrospectivo de los últimos ocho años;Dermatol. Rev. Mex.,2012 4. Basal Cell Carcinoma: Evidence-Based Medicine and Review of Treatment Modalities;Kwasniak;Int. J. Dermatol.,2011 5. Basal Cell Carcinoma of the Skin (Part 1): Epidemiology, Pathology and Genetic Syndromes;Silva;Future Oncol.,2015
|
|